FDA

FDA Articles

Here 24/7 Wall St. takes a look at a recent report by Canaccord Genuity regarding to biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest...
Seattle Genetics shares dipped on Monday following an update from the FDA on Adcetris for certain lymphomas.
The demand for drugs to treat erectile dysfunction has risen to meet the needs of an aging population and to help combat disease-related causes.
Alkermes shares dropped early on Friday after the company anncounced the results from its most recent meeting with the U.S. Food and Drug Administration.
Merck shares were up slightly on Wednesday after the pharma giant gave another key update for its KEYTRUDA line. The firm announced that the U.S. Food and Drug Administration (FDA) has approved...
CRISPR Therapeutics shares made a handy gain on Thursday after the company announced a key FDA decision concerning its collaboration with Vertex Pharmaceuticals.
AcelRx shares made a solid gain on Wednesday despite a less-than-favorable update from the FDA. However, there is a vote for approval on Friday. and that seems to be what investors are optimistic...
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the remainder of October.
The FDA is cracking down on smoking, but not what is traditionally considered smoking. The agency is going after e-cigarette manufacturers, as teen smokers (vapers) have reached epidemic levels.
Clovis Oncology shares jumped on Tuesday after the U.S. Food and Drug Administration (FDA) gave a critical update.
Here is a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of October.
Protagonist Therapeutics shares made a solid gain on Thursday after the company announced a key update from the FDA.
Acadia Pharmaceuticals shares popped after the company announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid...
Adverum Biotechnologies shares made a handy gain on Thursday after the company announced a key update from the FDA.
Clovis shares might not be showing it now, but the company is facing some heat from the SEC over charges of misleading investors about the company’s developmental lung cancer drug.